Ontology highlight
ABSTRACT:
SUBMITTER: Takezako N
PROVIDER: S-EPMC7547551 | biostudies-literature | 2020 Oct
REPOSITORIES: biostudies-literature
Takezako Naoki N Shibayama Hirohiko H Handa Hiroshi H Hagiwara Shotaro S Ozaki Shuji S Suzuki Kenshi K Kosugi Hiroshi H Ri Masaki M Sugiura Isamu I Choi Ilseung I Miyamoto Toshihiro T Iida Shinsuke S
International journal of hematology 20201010 2
A.R.R.O.W. evaluated the superiority of once-weekly carfilzomib plus dexamethasone (Kd) 20/70 mg/m<sup>2</sup> vs. twice-weekly Kd 20/27 mg/m<sup>2</sup> based on progression-free survival (PFS) in relapsed and/or refractory multiple myeloma patients. Forty Japanese patients (once-weekly arm, n = 26; twice-weekly arm, n = 14) were randomized in A.R.R.O.W. In the Japanese subgroup of A.R.R.O.W., median PFS was 14.8 months (95% confidence interval [CI], 7.5-not evaluable [NE]) and 9.7 months (95% ...[more]